Yehuda Handelsman
Overview
Explore the profile of Yehuda Handelsman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
5555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masson W, Barbagelata L, Lobo M, Nogueira J, Handelsman Y
J Clin Lipidol
. 2025 Feb;
PMID: 39893110
Background: Obicetrapib is a next-generation, oral, selective cholesteryl ester transfer protein inhibitor known to significantly affect atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (Non-HDL-C),...
2.
Handelsman Y
Am J Manag Care
. 2024 Dec;
30(10 Suppl):S189-S196.
PMID: 39705195
In recent years, evidence has continued to mount showing a strong relationship between diabetes, cardiovascular disease, and chronic kidney disease. This, in turn, has driven a shift to a more...
3.
Liu L, Ke W, Li H, Li F, Fan G, Kuang J, et al.
BMJ
. 2024 Oct;
387:e080122.
PMID: 39406449
Objective: To evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients...
4.
DeFronzo R, Auchus R, Bancos I, Blonde L, Busch R, Buse J, et al.
BMJ Open
. 2024 Jul;
14(7):e081121.
PMID: 39013654
Introduction: Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary,...
5.
Christofides E, Stankiewicz A, Denham D, Bellido D, Franek E, Nakhle S, et al.
Endocr Pract
. 2024 Jun;
30(9):810-816.
PMID: 38876181
Objective: To compare the immunogenicity, safety, and efficacy of Gan & Lee insulin glargine (GL Glargine) with that of the originator insulin glargine (Lantus) in patients with type 1 diabetes...
6.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, et al.
Metabolism
. 2024 Jun;
159:155931.
PMID: 38852020
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and...
7.
Ibrahim M, Ba-Essa E, Baker J, Cahn A, Ceriello A, Cosentino F, et al.
Diabetes Metab Res Rev
. 2023 Dec;
40(3):e3755.
PMID: 38115715
In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important...
8.
Morales J, Handelsman Y
J Am Coll Cardiol
. 2023 Jul;
82(2):161-170.
PMID: 37407115
Chronic kidney disease (CKD) and cardiovascular disease (CVD) have a significant inter-relationship in patients with diabetes. Controlling blood pressure, dyslipidemia, and glucose levels is a common treatment approach to managing...
9.
Handelsman Y, Butler J, Bakris G, DeFronzo R, Fonarow G, Green J, et al.
J Diabetes Complications
. 2023 Jan;
37(2):108389.
PMID: 36669322
Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to...
10.
Hamid A, Handelsman Y, Butler J
J Card Fail
. 2022 Aug;
28(11):1642-1645.
PMID: 35973620
No abstract available.